Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Yishen Qutong Granules Combined With Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: A Multicentre, Randomised, Triple-Blind, Placebo-Controlled Trial

NCT07390565 is registered in ClinicalTrials.gov with LI FENG as lead sponsor.

NCT NCT07390565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07390565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Yishen Qutong Granules Combined With Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: A Multicentre, Randomised, Triple-Blind, Placebo-Controlled Trial
Lead sponsor
LI FENG
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
February 17, 2026
Completion date
June 30, 2028
Enrollment
308 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer (sclc)